Drugs / AVTX-801
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05402384 | Jan 2027 → Mar 2028 expected | SLC35A2-congenital disorder of glycosylation | Eva Morava-Kozicz | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05402332 | Oct 2026 → Mar 2028 expected | PGM1-congenital disorder of glycosylation | Eva Morava-Kozicz | Not yet recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AVTX-801 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05402332 ↗ |